SOHO 2024: Focus on Leukemia

Andrew MorenoChronic Myeloid Leukemia | November 13, 2024
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
Andrew MorenoChronic Lymphocytic Leukemia | November 13, 2024
Venetoclax plus ibrutinib was associated with lower rates of mortality and serious adverse events than the control regimens.
Andrew MorenoAcute Myeloid Leukemia | November 13, 2024
MDS-related gene mutations and number of mutations did not correlate with worse outcomes.
Advertisement
Andrew MorenoAcute Lymphoblastic Leukemia | November 13, 2024
The one-year overall survival rate of 90%, and the MRD negativity rate was 94%.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Ponatinib demonstrated long-term efficacy and manageable safety in patients with highly resistant, chronic phase CML.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Achieving deep molecular response has allowed for treatment discontinuation, making TFR a main goal of therapy.
Advertisement
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Olverembatinib was well tolerated and showed strong antileukemic activity in patients with chronic phase CML.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Asciminib continues to demonstrate favorable safety and tolerability compared to TKIs in patients with chronic phase CML.
Rebecca AraujoChronic Myeloid Leukemia | September 23, 2024
Age ≥65 years, arrhythmia, and cardiogenic shock were associated with a significantly higher rate of acute heart failure.
Rebecca AraujoChronic Lymphocytic Leukemia | September 23, 2024
Liso-cel demonstrated clinical benefit and manageable safety, with low incidences of grade ≥3 CRS.
Rebecca AraujoAcute Myeloid Leukemia | September 23, 2024
Length of venetoclax dosing and prior chemotherapy exposure were associated with prolonged hematological recovery.
Rebecca AraujoAcute Lymphoblastic Leukemia | September 23, 2024
The phase Ib/II FELIX trial found that obe-cel is effective for the treatment of relapsed or refractory adult B-cell ALL.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Fixed-duration ibrutinib plus venetoclax provides durable PFS in patients with CLL.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Ibrutinib provides significantly longer PFS and OS benefits in CLL when compared to chlorambucil.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Oral targeted inhibitors are a viable treatment for patients with CLL with severe renal dysfunction.
Cailin ConnerChronic Lymphocytic Leukemia | September 20, 2024
Switching rates within 60 days were lower for patients treated with zanubrutinib compared with acalabrutinib and ibrutinib.
Cailin ConnerAcute Myeloid Leukemia | September 6, 2024
Quizartinib significantly improves long-term survival in FLT3-ITD+ AML by achieving deep and sustained reductions in MRD.
Cailin ConnerAcute Myeloid Leukemia | September 6, 2024
Combining HMAs with venetoclax significantly improves remission rates and survival but requires more healthcare resources.
Cailin ConnerAcute Myeloid Leukemia | September 9, 2024
SLC40A1 mRNA levels were significantly higher in AML patients compared with controls and were associated with poorer OS.
Cailin ConnerAcute Myeloid Leukemia | September 6, 2024
Achieving complete hematologic recovery before subsequent treatment cycles is associated with improved survival outcomes.
Advertisement
Advertisement
Editorial Board